Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
Summary: This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheuma...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | The Lancet Regional Health. Europe |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776223001254 |
| _version_ | 1797752883089768448 |
|---|---|
| author | Brigitte Michelsen Mikkel Østergaard Michael John Nissen Adrian Ciurea Burkhard Möller Lykke Midtbøll Ørnbjerg Jakub Zavada Bente Glintborg Alan MacDonald Karin Laas Dan Nordström Bjorn Gudbjornsson Florenzo Iannone Pasoon Hellmand Tore Kristian Kvien Ana Maria Rodrigues Catalin Codreanu Ziga Rotar Isabel Castrejón Fernández Johan Karlsson Wallman Jiri Vencovsky Anne Gitte Loft Maureen Heddle Sigrid Vorobjov Anna-Mari Hokkanen Gerdur Gröndal Marco Sebastiani Marleen van de Sande Eirik Klami Kristianslund Maria José Santos Corina Mogosan Matija Tomsic Federico Díaz-González Daniela Di Giuseppe Merete Lund Hetland |
| author_facet | Brigitte Michelsen Mikkel Østergaard Michael John Nissen Adrian Ciurea Burkhard Möller Lykke Midtbøll Ørnbjerg Jakub Zavada Bente Glintborg Alan MacDonald Karin Laas Dan Nordström Bjorn Gudbjornsson Florenzo Iannone Pasoon Hellmand Tore Kristian Kvien Ana Maria Rodrigues Catalin Codreanu Ziga Rotar Isabel Castrejón Fernández Johan Karlsson Wallman Jiri Vencovsky Anne Gitte Loft Maureen Heddle Sigrid Vorobjov Anna-Mari Hokkanen Gerdur Gröndal Marco Sebastiani Marleen van de Sande Eirik Klami Kristianslund Maria José Santos Corina Mogosan Matija Tomsic Federico Díaz-González Daniela Di Giuseppe Merete Lund Hetland |
| author_sort | Brigitte Michelsen |
| collection | DOAJ |
| description | Summary: This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations. |
| first_indexed | 2024-03-12T17:11:00Z |
| format | Article |
| id | doaj.art-1fb7ead5c4ae4f17b05c44782857a4ee |
| institution | Directory Open Access Journal |
| issn | 2666-7762 |
| language | English |
| last_indexed | 2024-03-12T17:11:00Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Europe |
| spelling | doaj.art-1fb7ead5c4ae4f17b05c44782857a4ee2023-08-06T04:38:28ZengElsevierThe Lancet Regional Health. Europe2666-77622023-10-0133100706Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen0Mikkel Østergaard1Michael John Nissen2Adrian Ciurea3Burkhard Möller4Lykke Midtbøll Ørnbjerg5Jakub Zavada6Bente Glintborg7Alan MacDonald8Karin Laas9Dan Nordström10Bjorn Gudbjornsson11Florenzo Iannone12Pasoon Hellmand13Tore Kristian Kvien14Ana Maria Rodrigues15Catalin Codreanu16Ziga Rotar17Isabel Castrejón Fernández18Johan Karlsson Wallman19Jiri Vencovsky20Anne Gitte Loft21Maureen Heddle22Sigrid Vorobjov23Anna-Mari Hokkanen24Gerdur Gröndal25Marco Sebastiani26Marleen van de Sande27Eirik Klami Kristianslund28Maria José Santos29Corina Mogosan30Matija Tomsic31Federico Díaz-González32Daniela Di Giuseppe33Merete Lund Hetland34Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Research Unit, Sørlandet Hospital, Kristiansand, Norway; Corresponding author. Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, DenmarkDepartment of Rheumatology, Geneva University Hospital, Geneva, SwitzerlandDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, SwitzerlandDepartment of Rheumatology and Immunology, Inselspital - University Hospital Bern, SwitzerlandCopenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, DenmarkInstitute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech RepublicDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, DenmarkNHS Grampian, Scotland, UKDepartment of Rheumatology, East-Tallinn Central Hospital, Tallinn, EstoniaDepartments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, FinlandCentre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, IcelandRheumatology Unit, DETO, University of Bari, ItalyDepartment of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, the NetherlandsCenter for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, NorwayReuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal; EpiDoC Unit, Nova Medical School, Lisbon, Portugal; Rheumatology Unit, Hospital dos Lusíadas, Lisbon, PortugalCenter for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, RomaniaDepartment of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, Universitiy of Ljubljana, Ljubljana, SloveniaDepartment of Rheumatology, Hospital General, Universitario Gregorio Marañón, Madrid, Spain; Faculty of Medicine, Complutense University of Madrid, SpainDepartment of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, SwedenInstitute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech RepublicDepartment of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, DenmarkAberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, UKNational Institute for Health Development, Tallinn, EstoniaDepartment of Medicine, Helsinki University and Helsinki University Hospital, Helsinki, FinlandCentre for Rheumatology Research, Landspitali University Hospital, Reykjavik, IcelandRheumatology Unit, University of Modena and Reggio Emilia, Modena, ItalyDepartment of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection & Immunity, Amsterdam, the Netherlands; Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, the NetherlandsCenter for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, NorwayDepartment of Rheumatology, Hospital Garcia de Orta, Almada, Portugal; Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, PortugalCenter for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, RomaniaDepartment of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, Universitiy of Ljubljana, Ljubljana, SloveniaDepartment of Internal Medicine, Dermatology and Psychiatry, Universidad de la Laguna, La Laguna, Spain; Rheumatology Service, Hospital Universitario de Canarias, La Laguna, SpainClinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, SwedenCopenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, DenmarkSummary: This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.http://www.sciencedirect.com/science/article/pii/S2666776223001254Health policyPsoriatic arthritisAxial spondyloarthritisTreatment recommendations |
| spellingShingle | Brigitte Michelsen Mikkel Østergaard Michael John Nissen Adrian Ciurea Burkhard Möller Lykke Midtbøll Ørnbjerg Jakub Zavada Bente Glintborg Alan MacDonald Karin Laas Dan Nordström Bjorn Gudbjornsson Florenzo Iannone Pasoon Hellmand Tore Kristian Kvien Ana Maria Rodrigues Catalin Codreanu Ziga Rotar Isabel Castrejón Fernández Johan Karlsson Wallman Jiri Vencovsky Anne Gitte Loft Maureen Heddle Sigrid Vorobjov Anna-Mari Hokkanen Gerdur Gröndal Marco Sebastiani Marleen van de Sande Eirik Klami Kristianslund Maria José Santos Corina Mogosan Matija Tomsic Federico Díaz-González Daniela Di Giuseppe Merete Lund Hetland Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe The Lancet Regional Health. Europe Health policy Psoriatic arthritis Axial spondyloarthritis Treatment recommendations |
| title | Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe |
| title_full | Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe |
| title_fullStr | Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe |
| title_full_unstemmed | Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe |
| title_short | Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe |
| title_sort | differences and similarities between the eular asas eular and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across europe |
| topic | Health policy Psoriatic arthritis Axial spondyloarthritis Treatment recommendations |
| url | http://www.sciencedirect.com/science/article/pii/S2666776223001254 |
| work_keys_str_mv | AT brigittemichelsen differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT mikkeløstergaard differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT michaeljohnnissen differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT adrianciurea differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT burkhardmoller differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT lykkemidtbøllørnbjerg differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT jakubzavada differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT benteglintborg differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT alanmacdonald differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT karinlaas differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT dannordstrom differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT bjorngudbjornsson differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT florenzoiannone differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT pasoonhellmand differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT torekristiankvien differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT anamariarodrigues differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT catalincodreanu differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT zigarotar differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT isabelcastrejonfernandez differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT johankarlssonwallman differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT jirivencovsky differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT annegitteloft differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT maureenheddle differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT sigridvorobjov differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT annamarihokkanen differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT gerdurgrondal differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT marcosebastiani differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT marleenvandesande differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT eirikklamikristianslund differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT mariajosesantos differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT corinamogosan differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT matijatomsic differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT federicodiazgonzalez differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT danieladigiuseppe differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope AT meretelundhetland differencesandsimilaritiesbetweentheeularasaseularandnationalrecommendationsfortreatmentofpatientswithpsoriaticarthritisandaxialspondyloarthritisacrosseurope |